Therapy for Helicobacter pylori eradication
Conditions
Interventions
A group:Low frequency of vonoprazan combined with amoxicillin dual therapy
B group:Middle frequency of vonoprazan combined with amoxicillin dual therapy
C group:High frequency of vonoprazan combined with amoxicillin dual therapy
Sponsors
Department of Digestive Diseases, The 900th Hospital of the PLA Joint Logistic Support Force
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years without gender limitation; 2. Patients who were diagnosed with H. pylori infection through 13C/14C-urea breath test or histological evaluation; 3. Never received H.pylori eradication therapy.
Exclusion criteria
Exclusion criteria: 1. Those patients who had previously received PPI or H2 receptor antagonist 2 weeks before treatment, or had taken bismuth or antibacterial drugs 4 weeks before treatment; 2. Those patients who were allergic to potassium competitiveacidblocker(P-CAB) and penicillin drugs; 3. Those patients who suffered from gastrectomy before; 4 Patients with malignant tumors, severe heart, liver, or renal dysfunction; 5. Patients with pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of H. pylori eradication; | — |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of adverse events;The severity of adverse events; | — |
Countries
China
Contacts
Public ContactXiao-Jian He
Department of Digestive Diseases, The 900th Hospital of the PLA Joint Logistic Support Force
Outcome results
None listed